EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study

Afreen Karimkhan iD, Rong Xia, DeAnna Diaz iD, Abigail Wald, Steven Hodak, Babak Givi, Samer Khader, Liron Pantanowitz iD, Xiaoying Liu, Tamar C Brandler iD

Cancer Cytopathology · 2025

DOI: 10.1002/cncy.70045 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Cytopathology, 2025. Verfasst von Afreen Karimkhan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, New York University Langone Health, New York, New York, USA. Hauptthemen laut MEDLINE: Ribonuclease III, DEAD-box RNA Helicases, Mutation, Thyroid Nodule. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mutations in DICER1 are uncommon, poorly understood, and infrequently found in thyroid nodules.

Methods

The objective of this study was to investigate category III/IV thyroid nodules according to The Bethesda System for Reporting Thyroid Cytopathology with DICER1 gene mutations detected in fine‐needle aspiration cytology samples using ThyroSeq v3 molecular testing, with a focus on an exploration of the clinical and histopathologic outcomes of these nodules. In this multicenter study spanning more than 6 years, nodules were retrospectively analyzed for patient demographics, clinical course, cytologic features, and histopathology, where available.

Results

In total, 88 patients with somatic DICER1 mutations were included, with a mean age of 39.6 years and a female predominance. All mutations were in the somatic hotspot region, most commonly at the codon 5437 site. Most excised nodules showed benign histologic features (65.9%). Interestingly, the rate of malignancy was higher in this cohort compared with that in the national average.

Conclusions

DICER1 mutations appear to confer a higher risk of malignancy, but are not associated with any specific cytological or histopathological distinguishing features.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ribonuclease IIIDEAD-box RNA HelicasesMutationThyroid NoduleThyroid NeoplasmsThyroid GlandHumansFemaleMaleAdultMiddle AgedRetrospective StudiesBiopsy, Fine-NeedleAgedYoung AdultAdolescent

Stichwörter der Autor:innen

Bethesda category IIIDICER1 mutationscytologyprognosis

Substanzen

Ribonuclease IIIDICER1 protein, humanDEAD-box RNA Helicases

Autor:innen und Institutionen

  • Department of Pathology, New York University Langone Health, New York, New York, USA.
  • Department of Pathology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New York, USA.
  • Department of Pathology, University of Pittsburgh Medical College, Pittsburgh, Pennsylvania, USA.
  • Department of Otolaryngology, Memorial Sloan Kettering Center, New York, New York, USA.
  • Department of Pathology and Lab Medicine, Dartmouth Health and Geisel School of Medicine at Dartmouth, New Brunswick, New Jersey, USA.

ORCID-Profile: Afreen Karimkhan, DeAnna Diaz, Liron Pantanowitz, Tamar C Brandler

Zitieren

APA

Karimkhan, A., Xia, R., Diaz, D., Wald, A., Hodak, S., Givi, B., Khader, S., Pantanowitz, L., Liu, X., & Brandler, T. C. (2025). DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study. Cancer Cytopathology. https://doi.org/10.1002/cncy.70045

Vancouver

Karimkhan A, Xia R, Diaz D, Wald A, Hodak S, Givi B, et al. DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study. Cancer Cytopathology. 2025. doi:10.1002/cncy.70045

BibTeX
@article{Karimkhan2025,
  author = {Karimkhan, Afreen and Xia, Rong and Diaz, DeAnna and Wald, Abigail and Hodak, Steven and Givi, Babak and Khader, Samer and Pantanowitz, Liron and Liu, Xiaoying and Brandler, Tamar C},
  title = {DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study},
  journal = {Cancer Cytopathology},
  year = {2025},
  doi = {10.1002/cncy.70045}
}
Kostenlos starten →